EarliPoint Health Launches Project ALIGN to Advance Objective Measurement and Outcomes in Autism Care

Learn More →

Articles

Exploring the science, practice, and people shaping the future of early developmental evaluation.

Handling July 4th and Labor Day Crowds with a Child with Autism

Parades, festivals, and community celebrations are a hallmark of summer holidays. For many families, they are something to look forward to. For […]

…

Communicating Outcomes to Families: Turning Data Into Trust

Families don’t experience progress as a graph. They experience it as trust or doubt — a sense that therapy is working, or […]

…

VB-MAPP and Objective Measurement: How Eye-Tracking Complements Verbal Behavior Assessment

The VB-MAPP is one of the most widely used assessments in applied behavior analysis, and for good reason. It gives BCBAs a […]

…

VB-MAPP Alternatives: 6 ABA Assessments Compared (and How to Choose)

The VB-MAPP is one of the most widely used assessments in ABA, but it isn’t the only option — and it isn’t […]

…

Navigating the “Routine-Less” Summer Days With a Child With Autism

The last day of school felt like exhaling. No schedule, no rushed mornings, no homework pile by the door. But now it’s […]

…

How Long Does It Take to Get ADOS-2 Certified? Complete Guide for Clinicians

As autism prevalence reaches 1 in 31 children and diagnostic wait times for autism evaluations often extend four months or longer at […]

…
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder